Drug Profile


Alternative Names: OLT-1177

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Olatec Industries
  • Developer Olatec Therapeutics
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Interleukin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Musculoskeletal pain

Most Recent Events

  • 31 Mar 2017 Olatec Industries changed its name to Olatec Therapeutics
  • 23 Feb 2017 Phase-II clinical trials in Gout in Netherlands (PO) (EudraCT2016-000943-14)
  • 12 Dec 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top